US 12,448,457 B2
GP130 binding molecules and methods of use
Robert Kastelein, Menlo Park, CA (US); Deepti Rokkam, Menlo Park, CA (US); Patrick J. Lupardus, Menlo Park, CA (US); and Sandro Vivona, Menlo Park, CA (US)
Assigned to Synthekine, Inc., Menlo Park, CA (US)
Appl. No. 18/006,189
Filed by Synthekine, Inc., Menlo Park, CA (US)
PCT Filed Aug. 4, 2021, PCT No. PCT/US2021/044575
§ 371(c)(1), (2) Date Jan. 20, 2023,
PCT Pub. No. WO2022/031869, PCT Pub. Date Feb. 10, 2022.
Claims priority of provisional application 63/135,884, filed on Jan. 11, 2021.
Claims priority of provisional application 63/078,745, filed on Sep. 15, 2020.
Claims priority of provisional application 63/061,562, filed on Aug. 5, 2020.
Prior Publication US 2024/0199737 A1, Jun. 20, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 37/02 (2006.01); C07K 14/715 (2006.01); C07K 16/46 (2006.01); C07K 19/00 (2006.01); C12N 15/63 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2866 (2013.01) [A61P 37/02 (2018.01); C07K 14/7155 (2013.01); C07K 16/2803 (2013.01); C07K 16/46 (2013.01); C07K 16/468 (2013.01); C07K 19/00 (2013.01); C12N 15/63 (2013.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2319/40 (2013.01)] 20 Claims
 
1. A gp130 binding molecule that specifically binds to the extracellular domain of gp130, wherein the gp130 binding molecule comprises a single domain antibody comprising
a complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:8, a CDR2 comprising the amino acid sequence of SEQ ID NO:9, and a CDR3 comprising the amino acid sequence of SEQ ID NO:10; or
a CDR1 comprising the amino acid sequence of SEQ ID NO:11, a CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a CDR3 comprising the amino acid sequence of SEQ ID NO:13; or
a CDR1 comprising the amino acid sequence of SEQ ID NO:14, a CDR2 comprising the amino acid sequence of SEQ ID NO:15, and a CDR3 comprising the amino acid sequence of SEQ ID NO:16; or
a CDR1 comprising the amino acid sequence of SEQ ID NO:17, a CDR2 comprising the amino acid sequence of SEQ ID NO:18, and a CDR3 comprising the amino acid sequence of SEQ ID NO:19; or
a CDR1 comprising the amino acid sequence of SEQ ID NO:20, a CDR2 comprising the amino acid sequence of SEQ ID NO:21, and a CDR3 comprising the amino acid sequence of SEQ ID NO:22; or
a CDR1 comprising the amino acid sequence of SEQ ID NO:23, a CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a CDR3 comprising the amino acid sequence of SEQ ID NO:25.